Clinical trials in Limoges – page 4

469 clinical trials in Limoges, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Limoges at a glance

469

clinical trials

Research sites1

Quick filters

469 trials in Limoges

Open in trial search

Non-small cell lung cancer stage IIIA+2

Recruiting

Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment

Registered drugNo placebo

Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

B-cell type acute leukaemia

Recruiting

Study of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia

Registered drugNo placebo

Study of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years
Substances:Blinatumomab
Sponsor:Universita Degli Studi Di Milano Bicocca

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Study of Revumenib and Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia with NPM1 Gene Mutation

Registered drug

Study of Revumenib and Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia with NPM1 Gene Mutation

Registered drug

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Cytarabine
Sponsor:Syndax Pharmaceuticals Inc.

Contact Research Centre

Ovarian cancer

Recruiting

A Study of Mirvetuximab Soravtansine, Carboplatin, and Bevacizumab in Adults with Ovarian Cancer

Registered drugNo placebo

A Study of Mirvetuximab Soravtansine, Carboplatin, and Bevacizumab in Adults with Ovarian Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Cervix carcinoma

Recruiting

A Study of Sacituzumab Tirumotecan, Pembrolizumab, and Bevacizumab for Patients with Metastatic Cervical Cancer That Has Spread or Returned

Registered drugNo placebo

A Study of Sacituzumab Tirumotecan, Pembrolizumab, and Bevacizumab for Patients with Metastatic Cervical Cancer That Has Spread or Returned

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Colitis ulcerative

Recruiting

Testing icotrokinra compared to placebo for adults and adolescents with moderately to severely active ulcerative colitis

Investigational

Testing icotrokinra compared to placebo for adults and adolescents with moderately to severely active ulcerative colitis

Investigational

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Icotrokinra
Sponsor:Janssen Cilag International

Contact Research Centre

Sepsis

Recruiting

Testing a Drug Combination for Personalized Sepsis Treatment in Children and Adults with Severe Blood Infection

Registered drugNo placebo

Testing a Drug Combination for Personalized Sepsis Treatment in Children and Adults with Severe Blood Infection

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Anakinra
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

Registered drugNo placebo

Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:Unicancer

Contact Research Centre

Endometrial cancer metastatic

Recruiting

A Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment

Registered drugNo placebo

A Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:AZD8205
Sponsor:AstraZeneca AB

Contact Research Centre

Neoplasm malignant

Recruiting

A Study of MK-1084 Alone and Combined with Cetuximab for People with Advanced Solid Tumors that Have a KRAS G12C Gene Change

Registered drugNo placebo

A Study of MK-1084 Alone and Combined with Cetuximab for People with Advanced Solid Tumors that Have a KRAS G12C Gene Change

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cetuximab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Renal cell carcinoma

Recruiting

A Study of Belzutifan and Zanzalintinib Compared to Cabozantinib in Patients with Advanced Kidney Cancer that Returned After Previous Treatment

Registered drugNo placebo

A Study of Belzutifan and Zanzalintinib Compared to Cabozantinib in Patients with Advanced Kidney Cancer that Returned After Previous Treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Belzutifan
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Gastrooesophageal cancer+1

Recruiting

A study comparing trifluridine, tipiracil, and fruquintinib versus trifluridine and tipiracil alone for patients with metastatic stomach or esophageal cancer

Registered drugNo placebo

A study comparing trifluridine, tipiracil, and fruquintinib versus trifluridine and tipiracil alone for patients with metastatic stomach or esophageal cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Fruquintinib
Sponsor:Fondation Franc.Cancerologie Digestive

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Limoges

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on multiple myeloma treatments and novel therapies for various cancers. Current trials investigate innovative approaches for colorectal cancer and esophageal squamous cell carcinoma.

Multiple Myeloma Treatment Optimization
Advanced Biliary Tract Cancer Therapy
Breast Cancer Treatment Innovation

Studies are evaluating new combination therapies and maintenance treatments to improve patient outcomes.

02 Neurological Disorders

Critical research into Amyotrophic Lateral Sclerosis (ALS) treatments, testing new therapeutic compounds and combinations to slow disease progression.

ALS Treatment Development
Novel Drug Combinations
Disease Progression Management

Multiple trials are exploring innovative approaches to improve quality of life for ALS patients.

03 Immunology and Transplantation

Advanced research in kidney transplantation and immune-related conditions, including studies on preventing rejection and managing immunosuppression.

Transplant Rejection Prevention
Immunotherapy Developments
Infection Prevention Strategies

Innovative approaches to improve transplant outcomes and manage immune system responses.

Back to France All countries